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Erythropoietin (EPO) is a hypoxia-induced hormone produced in the kidneys that stimulates
hematopoiesis in the bone marrow. However, recent studies have also shown important
nonhematopoietic effects of EPO. A functional EPO receptor is found in the cardiovascular
system, including endothelial cells and cardiomyocytes. In animal studies, treatment with
EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the
extent of apoptosis. In the longer term, EPO may promote ischemia-induced neovascular-
ization, either by stimulating endothelial cells in situ or by mobilizing endothelial progenitor
cells from bone marrow. The effects of EPO in the ischemic heart support the concept of
EPO as a pleiotropic, tissue-protective agent for other organs expressing the EPO receptor.
We recently performed a first randomized clinical study showing the safety and feasibility of
EPO administration in patients with acute myocardial infarction. Future clinical studies are
warranted to translate the beneficial effects of EPO from basic experiments to cardiac
patients. (J Am Coll Cardiol 2006;48:2161–7) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.031Cardiology Foundation
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urythropoietin (EPO) is a hematopoietic hormone pro-
uced primarily in the kidneys in response to hypoxia (1).
ffects of EPO in the bone marrow are mediated by binding
o a specific transmembrane receptor (EPO-R), which is
xpressed primarily by hematopoietic progenitor cells (2).
ubsequent dimerization of EPO-R leads to activation of
umerous intracellular pathways (PI3K/Akt, mitogen-
ctivated protein kinase [MAPK], STAT-5) associated
ith cell survival (3). Erythropoietin primarily inhibits the
poptosis of erythroid precursor cells and thus increases
heir survival. On the other hand, EPO synergistically with
ther growth factors promotes the proliferation and matura-
ion of erythroid progenitor cells (4).
The synthesis of various forms of recombinant human
PO (rhEPO) represented a breakthrough in the treatment
f anemia caused by EPO deficiency due to chronic kidney
isease (CKD) (5). At present, rhEPO is approved also for
he treatment of cancer patients with anemia of chronic
isease or anemia induced by chemotherapy or radiotherapy
6), in patients with myelodysplastic syndromes, and as a
rophylactic treatment to reduce the need for transfusions
efore major surgery (1).
Although EPO is traditionally viewed as a hematopoietic
ormone, the finding of EPO-Rs outside the hematopoietic
issue (endothelial cells, neurons, trophoblast cells)
rompted the search for nonhematopoietic effects of EPO
1). Experimental studies have shown the protective effect of
From the Departments of *Clinical Pharmacology and †Cardiology, University
edical Center Groningen, University of Groningen, Groningen, the Netherlands.
xperimental studies performed by our group were partly supported by an unrestricted
ducational grant from Amgen, Inc. (Thousand Oaks, California).e
Manuscript received April 5, 2006; revised manuscript received August 10, 2006,
ccepted August 14, 2006.xogenous EPO treatment in different tissues. Systemic
dministration of EPO in the rat model of focal brain
schemia reduced the infarct volume by 50% to 75% (7). In
he kidney, treatment with EPO significantly reduced the
enal injury and dysfunction associated with ischemia/
eperfusion (I/R) in rodents (8). Other reports documented
he benefit of EPO therapy in the setting of hypoxic retinal
isease (9), gastrointestinal ischemia (10), and the cardio-
ascular system (11–14).
PO AND EPO-R IN THE CARDIOVASCULAR SYSTEM
he expression of EPO-R was found in a variety of cell lines
riginated from the cardiovascular system. In vitro, EPO-R
s synthesized and is present on the surface of human
ascular endothelial cells (15), and administration of EPO
revents apoptosis of endothelial cells subjected to hypoxia
hrough direct modulation of PI3K/Akt phosphorylation
16). The expression of EPO-R also was shown in neonatal
17) and adult (18) rat cardiac myocytes. Similar to endo-
helial cells, EPO prevented the apoptosis of cardiomyo-
ytes by means of activating PI3/Akt pathway (17).
In vivo, EPO-R is expressed in normal rat cardiac
issue. Immunostaining for EPO-R is predominantly
bserved in interstitial cells, including endothelial cells
nd fibroblasts, with weak expression in cardiomyocytes
19). Recently, EPO-R expression was confirmed also in
uman heart tissue. Both ventricular myocytes and endo-
helial cells in the adult human heart were positive for the
PO-R (20). Expression of EPO itself in the heart, either
nder normal or hypoxic conditions, has not been reliably
stablished (11).
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Erythropoietin in Cardiac Ischemia December 5, 2006:2161–7An entirely new concept of EPO-mediated protection
as introduced by Leist et al. (21), through generating
utants of EPO, which do not bind to the classical dimeric
PO-R and lack hematopoietic activity but nevertheless
aintain their protective properties in various models of
issue and organ ischemia. This could suggest existence of
ifferent types of receptors needed for hematopoietic and
onhematopoietic effects of EPO. Recently, a putative cell
urface receptor configuration mediating the tissue-
rotective EPO effects was identified, consisting of the
PO-receptor and beta-common receptor, which is present
lso in the myocardium (22).
Abbreviations and Acronyms
CHF  chronic heart failure
CKD  chronic kidney disease
EPC  endothelial progenitor cell
EPO  erythropoietin
EPO-R erythropoietin receptor
I/R  ischemia/reperfusion
LV  left ventricle/ventricular
MI  myocardial infarction
rhEPO  recombinant human erythropoietin
able 1. Experimental Studies Showing Acute Cardioprotection
Animal Model Dosage of EPO
x vivo I/R Isolated rat heart,
30 min/2 h I/R
5,000 IU/kg 24 h befor
I/R
Isolated rabbit heart,
30 min/35 min I/R
0.5–10 IU/ml, 15 min
before I/R
Isolated rat heart,
40 min/2 h I/R
10 IU/ml throughout th
protocol
Isolated rat heart,
20 min/25 min I/R
10 IU/ml before I/R
Isolated rat heart,
20 min/40 min I/R
10 IU/ml at various tim
points during I/R
n vivo I/R Rat, 30 min/7 days I/R 5,000 IU/kg for 7
consecutive days
Rabbit, 30 min/3 days
I/R
5,000 IU/kg at the tim
of reperfusion
Rat, 40 min/24 h I/R 5,000 IU/kg 30 min
after ischemia
Rat, 40 min/24 h I/R 5,000 IU/kg at differen
time points during I/
Dog, 90 min/6 h I/R 100–1,000 IU/kg just
before reperfusion
n vivo permanent
occlusion
Rat, 60 min 5,000 IU/kg after
coronary artery
ligation
Rabbit, 3-day follow-up 5,000 IU/kg at the tim
of coronary artery
ligation
Rat, 8-week follow-up 3,000 IU/kg after
coronary occlusion
Rat, 9-weeks follow-up 40 g/kg darbepoetin
after coronary
occlusionTP  adenosine triphosphate; I/R  ischemia/reperfusion; IU  international units
itogen-activated protein kinase; PI3K/Akt  phosphatidylinositol 3-kinase/Akt kinase.CUTE CARDIOPROTECTIVE EFFECTS OF EPO
n hematopoietic and nonhematopoietic tissues alike, EPO
as shown to activate pathways leading to inhibition of
poptosis. Apoptosis, one of the major forms of cell death,
as been implicated in different cardiovascular diseases. In
yocardial infarction (MI), apoptosis might be a determi-
ant of the final infarct size, and its extent depends on the
resence of postischemic reperfusion (23).
Recently, numerous ex vivo (in isolated rodent and rabbit
earts) and in vivo studies have shown a protective role of
PO during ischemic and I/R injury in the heart (Table 1).
Pretreatment of adult rats with EPO (5,000 IU/kg) 24 h
receding I/R increased the functional recovery of isolated
earts during reperfusion (11). This was accompanied by
rotection against apoptosis, as measured by the number of
erminal deoxynucleotidyl transferase biotin-dUTP nick
nd labeling-positive cells and activity of proapoptotic
arker caspase-3. The mechanism of EPO-mediated pro-
ection was shown by blockade of these effects with a
pecific inhibitor of the PI3K/Akt pathway (24). The
nvolvement of signal transducing pathways was further
lucidated by Shi et al. (25) in a rabbit isolated-heart model
n which the cardioprotective effects of EPO were abolished
y inhibitors of 2 different MAPK (p38 and p42/44). In the
Erythropoietin (EPO)
Outcome Reference(s)
Increased functional recovery, apoptosis inhibition (11,24)
Increased recovery through activation of MAPK and
potassium channels
(25)
Improved recovery of LV pressure, coronary flow,
reduction of cellular damage
(19)
Improved postischemic recovery of LVDP, preservation
of ATP levels in ischemic myocardium
(18)
PI3K/Akt-dependent postischemic EPO
cardioprotection
(26)
Reduction in cardiomyocyte loss by 50%,
normalization of hemodynamic function
(12)
Decreased infarct size, enhancement of LV function,
mitigation of myocardial cells apoptosis
(14,31)
Reduced infarct size, dependent on MAPK, PI3K/Akt
activation
(27)
Reduction in infarct size and apoptosis even when EPO
administered after the onset of reperfusion
(13)
Reduction in infarct size with low dose, via PI3K/Akt-
dependent pathway
(32)
Reduction in apoptosis (17)
Improvement in inotropic reserve, inhibition of
apoptosis
(14)
Smaller infarct size, prevention of LV dilation,
improved LV ejection fraction
(34)
Reduction in infarct size, improved LV function,
increased capillary density
(42)With
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December 5, 2006:2161–7 Erythropoietin in Cardiac Ischemiaame study, potassium channel inhibitors also blocked the
PO effects, indicating a role of potassium channels in
PO-mediated preservation of heart function, possibly
ause by reduction of calcium overload. Hanlon et al. (26)
howed the importance of another protein kinase, protein
inase C (PKC), in EPO-mediated cardioprotection. Inter-
stingly, although activation of PKC by EPO is required
efore and during ischemia, postischemic cardioprotection
s dependent on PI3K/Akt and MAPK pathways (26,27).
n a study performed by our group, perfusion of isolated rat
earts with EPO during I/R attenuated the deterioration of
eft ventricular pressure and coronary flow during the
eperfusion (19). Erythropoietin in this setting also reduced
ellular damage (purine outflow) and the number of cells
ntering apoptosis (active caspase-3 positive).
Although inhibition of apoptosis is widely accepted as a
echanism for EPO-mediated protection against acute
schemic injury, other possibilities should also be consid-
red. Pretreatment with EPO was shown to inhibit the
/R-induced myocardial inflammatory response (28) by
reventing the switching of myocytes to a proinflammatory
henotype, possibly also through up-regulation of nitric
xide production. Erythropoietin also can improve the
ardiac function by directly modulating the cardiac Na/K
ump (29) or stimulating the production of atrial natriuretic
eptide in cardiac atrium (30).
In the first in vivo study, Calvillo et al. (12) used a rat
odel of coronary I/R. Administration of EPO (5,000
U/kg/day) for 7 consecutive days after reperfusion reduced
he loss of cardiomyocytes by 50%, an extent sufficient to
ormalize hemodynamic function. However, the hematocrit
ncreased by 20% to 30% by the end of the study, and such
change alone may lead to improved cardiac function
erely by improving the delivery of oxygen.
In a rabbit model of MI, treatment with EPO at the time
f permanent coronary ligation resulted in a trend toward
educed infarct size and improvement of cardiac contractil-
ty and relaxation when measured 3 days later. Moreover,
he cardiac inotropic reserve, studied in response to beta-
drenergic receptor agonist, was significantly enhanced in
he EPO-treated group (14). In addition, EPO administra-
ion in an in vivo I/R was also found to be beneficial,
esulting in a significant reduction of infarct size, expressed
s a percentage of total ischemic area at risk (31). This
rotection was associated with the mitigation of myocardial
ell apoptosis. Furthermore, in line with the results from ex
ivo experiments, reduction of infarct size in vivo is depen-
ent on the activation of pro-survival pathways PI3K/Akt
nd MAPK (27).
The results of these studies raised 2 clinically important
ssues: that of the timing and the dosage of EPO adminis-
ration. In a study performed by our group (13), EPO
educed infarct size and inhibited apoptosis when adminis-
ered before the actual ischemic episode to until after the
nset of reperfusion, providing a broad window of oppor-
unity for the potential treatment of acute coronary syn- iromes. Because most of the previous experimental studies
sed high doses of EPO (1,000 to 5,000 IU/kg), Hirata et
l. (32) approached the issue of minimal EPO dose still
endering cardioprotection. The EPO treatment in a canine
odel of I/R reduced infarct size in a dose-dependent
anner, establishing the lowest effective dose of 100 IU/kg.
Recently, Fiordaliso et al. (33) definitely separated the
ematopoietic and nonhematopoietic effects of EPO by
sing a carbamylated derivate of EPO, lacking erythropoi-
tic activity. The carbamylated derivate of EPO adminis-
ration prevented cardiomyocyte loss and improved left
entricular (LV) function after I/R injury in rats.
Importantly, the effects of EPO administration persist
ver a longer period after the ischemic insult. Moon et al.
34) found that a single dose of EPO (3,000 IU/kg)
mmediately after coronary artery ligation in rats reduced
he infarct size to 15% to 25% that of untreated animals
xamined 8 weeks later. This reduction in myocardial
amage was accompanied by prevention of LV dilation and
mproved LV ejection fraction, as measured by repeated
chocardiography. It seems that EPO may protect the
yocardium also against more severe insults, such as per-
anent coronary occlusion, and this effect becomes even
ore pronounced with time.
ONG-TERM EFFECT OF EPO IN THE HEART
urrent therapy in patients after MI is focused on preven-
ion of ventricular remodeling and development of heart
ailure. Myocardial regeneration may offer possibilities that
ould improve cardiac function in these patients. Although
egeneration of cardiomyocytes by proliferation or transdif-
erentiation seems limited (35), the formation of new vessels
n noninfarcted parts may indirectly save cardiomyocytes
nd lead to improvement of ventricular function.
Two processes contribute to postnatal formation of blood
essels. Angiogenesis is the sprouting of new vessels from
xisting ones, whereas vasculogenesis refers to formation of
lood vessels from endothelial progenitor cells (EPCs).
hese cells are undifferentiated cells in peripheral tissues, or
erived from bone marrow, possessing the ability to mature
nto the cells lining the lumen of a blood vessel.
The EPCs also are mobilized in patients during acute
ardiac ischemic events (36). Recently, increased levels of
irculating EPCs were associated with reduced risk of death
rom cardiovascular causes in patients with confirmed cor-
nary artery disease (37). In the BOOST (BOne marrOw
ransfer to enhance ST-elevation infarct regeneration) trial,
ntracoronary infusion of autologous bone marrow cells
CD34) after MI resulted in improved global LV ejection
raction 6 months after cell transfer (38). However, the
ifference in LV ejection fraction was less convincing during
he long-term follow-up (39).
Erythropoietin was found to be a potent stimulus for
PC mobilization, which was associated with neovascular-zation of ischemic tissue (40). The effect of EPO on the
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Erythropoietin in Cardiac Ischemia December 5, 2006:2161–7ormation of new vessels has also been observed in an
xperimental model of stroke; EPO treatment, initiated
4 h after induction of stroke, increased the density of
icrovessels at the stroke boundary and improved neuro-
ogical function (41).
We addressed this issue in the heart, evaluating the effect
f EPO treatment on new vascular formation in an exper-
mental heart failure model (42). Rats were subjected to
oronary artery ligation, and therapy with the high-dose
PO analog darbepoetin (40 g/kg/3 weeks) was initiated
weeks after MI. Although not reducing infarct size, EPO
reatment significantly improved cardiac function. This
mprovement was coupled with an increased capillary-to-
yocyte ratio, indicating neovascularization.
In the clinical setting, treatment with rhEPO causes a
ignificant mobilization and functional activation of EPCs
n patients with renal anemia, as well as in healthy subjects
43). Interestingly, serum levels of EPO were also signifi-
antly correlated with the number of circulating EPCs in
atients with established coronary artery disease (40).
In addition to stimulating and mobilizing EPCs, directly
nhancing angiogenesis by EPO could also lead to neovas-
ularization; EPO stimulates proliferation of endothelial
ells in situ and their differentiation into vascular structures
44). In cultured human myocardial tissue, EPO stimulated
apillary outgrowth comparable with that of vascular endo-
helial growth factor (45).
However, the doses used in the previous studies, when
pplied to a clinical situation, could cause an EPO overdose
hat may lead to hypertension, seizures, vascular thrombosis,
nd death, possibly related to abruptly increased hematocrit
alues (46). This would be of an even greater concern in
atients with an already elevated cardiovascular risk.
This considerable clinical problem was addressed by
ahlmann et al. (47). In their model of progressive renal
isease, treatment with the low-dose EPO analog darbepo-
tin conferred tissue protection and preserved capillary
etwork in the kidney, but did not increase the hematocrit
evel. In a recent study performed by our group, we studied
he effects of low (nonerythropoietic)-dose darbepoetin in a
at model of post-MI heart failure. We showed that
arbepoetin treatment preserves cardiac function, even in
oses not affecting the hematocrit level. This is associated
ith an increased number of circulating EPCs and an
ncreased capillary-to-myocyte ratio (48). Stimulation of
PCs, without increasing the number of red blood cells,
mplies specific EPO dose-effect relationships in different
one marrow cells.
Although time-limited treatment with high-dose EPO
ay be beneficial and safe during acute ischemic injury, if
rolonged therapy is required (heart failure), drug regimens
sing low-dose EPO may be more suitable in avoiding the
dverse effects of the treatment. In this regard the nonhe-
atopoietic EPO derivates could also prove valuable; how-
ver, their effect on vasculogenesis and/or angiogenesis is
ot yet established. aLINICAL IMPLICATIONS
rythropoietin has been successfully used in clinical practice
or more than 2 decades, for the most part to treat anemia
n patients with CKD, caused by diminished production of
ndogenous EPO. In these patients, anemia is an estab-
ished risk factor for cardiovascular disease outcomes (49).
umerous smaller studies in predialysis and dialysis patients
ave shown a beneficial effect of anemia treatment with
PO on various surrogate cardiovascular end points (50,51).
owever, no conclusive data from randomized controlled
rials exist establishing the impact of anemia treatment on
ardiovascular and total mortality in patients with CKD
52). A recently started TREAT (Trial to Reduce Cardio-
ascular Events with Aranesp Therapy) study will determine
he effect of darbepoetin treatment on cardiovascular events
n CKD patients (52).
Anemia is also commonly observed in patients with
hronic heart failure (CHF) and is related to the severity of
he disease (53). Although the cause of anemia in these
atients is multifactorial, inadequate EPO production and a
lunted response to EPO in the bone marrow play a major
ole (54). Consequently, elevated EPO levels are associated
ith the severity of CHF and are a prognostic marker for
mpaired survival, independent of hemoglobin levels (55). It
eems that, although increased in absolute terms, EPO
evels in anemic CHF patients are still relatively low to
dequately stimulate the hematopoiesis in bone marrow.
igher levels of hematopoiesis inhibitors, such as N-acetyl-
eryl-aspartyl-lysyl-proline, could also counterbalance the
ffects of EPO (56). In a number of small studies, normal-
zation of hemoglobin levels with EPO in CHF patients
as associated with improved LV ejection fraction (57) and
nhanced exercise capacity (58). Although this amelioration
artly could be attributed to hemoglobin elevation and thus
he increased oxygen-binding capacity of blood, the nonhe-
atopoietic effects of EPO must also be considered. Re-
ently, 2 larger placebo-controlled phase II studies with
PO treatment in anemic CHF patients were conducted
hat also suggested potential beneficial effects both in terms
f quality of life and clinical end points. For this reason, a
arger trial aimed at assessing its effect on morbidity and
ortality is now being initiated (59).
The nonhematopoietic tissue-protective properties of
PO also may be beneficial in treatment of patients with
cute coronary syndromes. Currently, the emphasis in the
reatment of MI is on early reperfusion and hence limiting
he damage of cardiac ischemia. However, development of
ost-MI heart failure remains a major challenge despite
ptimal therapy. Erythropoietin could on one hand acutely
rotect myocardial cells against I/R-induced injury, and on
he other hand could attenuate the cardiac remodeling by
timulating the EPCs. Interestingly, high levels of endoge-
ous EPO in patients with a first MI who underwent
uccessful primary coronary intervention were found to be
ssociated with smaller infarcts, which was interpreted by
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December 5, 2006:2161–7 Erythropoietin in Cardiac Ischemiahe investigators as a possible endogenous, protective mech-
nism (60).
We recently performed a first safety and feasibility study
ith darbepoetin treatment in patients with an acute MI
61). In this single-center, investigator-initiated, prospec-
ive study we randomized 22 nonanemic patients with a first
cute MI to 1 bolus of 300 g darbepoetin alfa or no
dditional medication before primary coronary intervention.
dministration of darbepoetin was both safe and well
olerated. In the darbepoetin group, serum EPO levels
ncreased to 130 to 270 times that of controls within the
rst 24 h. Darbepoetin administration led to only small and
onsignificant changes in hematocrit levels, whereas EPCs
CD34/CD45) were significantly increased at 72 h.
espite a nonsignificantly longer time to treatment and
ore extensive baseline area at risk (cumulative ST-segment
levation) in the darbepoetin-treated group, LV ejection
raction after 4 months was similar in the 2 groups (52 3%
n darbepoetin vs. 48  5% in control group, p  NS),
ndicating a possible positive effect of darbepoetin treatment
n longer-term infarct healing and/or cardiac remodeling.
ONCLUSIONS
he traditionally hematopoietic hormone EPO is increas-
ngly recognized as a pleiotropic cytokine, with effects
eaching much further than stimulating red blood cell
roduction. Although already used in cardiology to correct
nemia in CHF patients, the nonhematopoietic effects of
PO also may be beneficial in nonanemic cardiovascular
igure 1. Biological functions of erythropoietin (EPO). Classical hemat
xperiments.atients.From the experimental studies, EPO seems to influence 2
rucial processes during cardiac ischemic injury, first by
cutely reducing the infarct size and inhibiting the apopto-
is, and second by promoting new vessels formation over a
onger time frame (Fig. 1). In clinics, randomized trials
hould translate the results of experimental studies and
nvestigate the effectiveness of EPO treatment in various
atient populations (acute MI, CHF).
Although treatment with EPO is generally well tolerated
nd safe, it may be associated with adverse effects such as
ypertension and thromboembolism. These side effects are
elated mainly to high-dose chronic EPO treatment, asso-
iated with increased hematocrit. Using variants of EPO
ithout hematopoietic effect but retaining tissue protective
ctivity could be useful in a clinical situation in which
ultiple EPO administrations would be warranted.
Future studies should determine a place for EPO in the
reatment of acute and chronic cardiac ischemia, which may
ave widespread implications for managing heart patients.
eprint requests and correspondence: Dr. Erik Lipšic, A.
eusinglaan 1, 9713 AV Groningen, the Netherlands. E-mail:
.lipsic@dz.nl.
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